HeraMED completed Phase 1 of its Lee Health digital pregnancy pilot, showing high virtual adoption and patient satisfaction, while advancing commercial talks with Philips and maintaining a solid cash position.
- Lee Health pilot shows 92% virtual visit adoption and NPS of 60
- Potential to free 3–5 prenatal appointment slots per pregnancy
- Expanded Philips commercial agreement nearing finalisation
- Operating cash outflow reduced to A$638K with A$2.93 million cash balance
- Approximately 4.6 quarters of funding available at quarter end
Strong Patient Endorsement from Lee Health Pilot
HeraMED Limited (ASX:HMD) has wrapped up Phase 1 of its Lee Health digital pregnancy care pilot, delivering compelling evidence of patient acceptance and operational efficiency. The pilot, involving 44 patients, recorded a 92% adoption rate of virtual prenatal visits and an outstanding Net Promoter Score (NPS) of 60 for the overall program, with the remote patient monitoring device itself scoring an exceptional 75. These metrics indicate strong patient advocacy and satisfaction, underpinning the viability of a digital-first maternity care model.
The pilot demonstrated that HeraMED’s digital pathway could reduce traditional in-person prenatal visits from around 15 to 11 per pregnancy, potentially freeing up 3 to 5 appointment slots. This has significant implications for clinical capacity and healthcare resource allocation, highlighting the potential to ease pressure on overstretched maternity services while maintaining patient engagement.
Scaling Up with Lee Health and Philips Partnership
Following the successful pilot, HeraMED and Lee Health are moving towards internal sign-off for Phase 2, which aims to transition from evaluation to scaled operational deployment. This next stage will further assess clinical outcomes, workflow efficiencies, health economics, and scalability within the Lee Health network.
Meanwhile, HeraMED is progressing towards an expanded commercial agreement with Philips, building on the foundation deal inked in November 2025. Discussions are advancing to broaden deployment across Philips’ US health system relationships. Both parties are actively coordinating joint sales presentations and hospital engagements, positioning HeraMED’s HeraCARE platform and HeraBEAT fetal monitor for integration into broader health system implementations.
Notably, the partnership is targeting opportunities arising from the US$50 billion Rural Health Transformation Program, which supports investments in remote care and digital health technologies. This could provide a significant deployment pathway for HeraMED’s solutions through Philips’ established networks.
Direct US Business Development and Financial Discipline
In parallel with partnerships, HeraMED’s US team continues direct engagement with health systems, payers, and strategic partners, focusing on enterprise maternity care pathways that enhance patient access, clinical capacity, and remote monitoring capabilities.
Financially, HeraMED reported a disciplined operating cost base, reducing quarterly cash outflow to A$638,000, down 25% from the prior quarter. Key expenses included administration (A$303K), staff costs (A$115K), and research and development (A$131K). The company ended the quarter with a robust cash balance of A$2.93 million, providing an estimated 4.6 quarters of funding runway. The June quarter also saw net proceeds of A$489,000 from equity placements and A$36,000 from option exercises.
CEO Anoushka Gungadin emphasised that the quarter’s work has strengthened HeraMED’s commercial foundations, positioning the company to convert advanced opportunities into larger-scale deployments and recurring revenue streams.
Bottom Line?
HeraMED’s strong pilot results and advancing partnerships lay a solid foundation, but the timing and scale of commercial rollouts remain key to watch.
Questions in the middle?
- How will Phase 2 deployment outcomes influence broader US adoption?
- What are the final terms and timeline for the expanded Philips agreement?
- Can HeraMED convert ongoing US business development into sustainable recurring revenue?